Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 250 versus MD 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 250 versus MD 76.
IOPAMIDOL-250 vs MD-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a non-ionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. It acts by increasing the radiodensity of blood vessels and organs.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
1-2 mL/kg intravenously for contrast imaging, not to exceed 200 mL total; dose and rate vary by procedure and patient weight.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
None Documented
None Documented
Terminal half-life 1.5-2 hours in normal renal function; may extend to 5-10 hours in severe renal impairment (CrCl <30 mL/min)
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Renal: >90% unchanged via glomerular filtration; biliary/fecal: <2%
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent